Pharmacokinetics, Mass Balance, and Biotransformation of a Novel Dual-Target Neuroprotectant [14C]Loberamisal (Y-3) in Humans: Clues from Rat Studies, Mechanistic Roles of UDP-Glucuronosyltransferase and Gut Microbiota
Publication date: Available online 17 November 2026 Source: Drug Metabolism and Disposition Author(s): Jian Ren, Taoyu Chen, Jingzhi Xue, Shu Yan, Yao Hua, Xintong Huang, Haonan Liu, Xingxing Diao, Feng Shao, Li Ding
Pharmacokinetics, Mass Balance, and Biotransformation of a Novel Dual-Target Neuroprotectant [14C]Loberamisal (Y-3) in Humans: Clues from Rat Studies, Mechanistic Roles of UDP-Glucuronosyltransferase and Gut Microbiota. // Drug Metabolism and Disposition. – URL: https://www.sciencedirect.com/science/article/pii/S0090955626007105?dgcid=rss_sd_all
Pharmacokinetics, Mass Balance, and Biotransformation of a Novel Dual-Target Neuroprotectant [14C]Loberamisal (Y-3) in Humans: Clues from Rat Studies, Mechanistic Roles of UDP-Glucuronosyltransferase and Gut Microbiota. Drug Metabolism and Disposition. https://www.sciencedirect.com/science/article/pii/S0090955626007105?dgcid=rss_sd_all
“Pharmacokinetics, Mass Balance, and Biotransformation of a Novel Dual-Target Neuroprotectant [14C]Loberamisal (Y-3) in Humans: Clues from Rat Studies, Mechanistic Roles of UDP-Glucuronosyltransferase and Gut Microbiota.” Drug Metabolism and Disposition.
@article{article43464,
title = {Pharmacokinetics, Mass Balance, and Biotransformation of a Novel Dual-Target Neuroprotectant [14C]Loberamisal (Y-3) in Humans: Clues from Rat Studies, Mechanistic Roles of UDP-Glucuronosyltransferase and Gut Microbiota},
journal = {Drug Metabolism and Disposition},
url = {https://www.sciencedirect.com/science/article/pii/S0090955626007105?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...